Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Blood (2020) 135 (24): 2182–2191.

https://doi.org/10.1182/blood.2019004710

Published: 2020

Includes: Supplemental data

Journal Articles

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Pushpendra Goswami, PhD MSc, BPharm, Tatiana Ionova, DSc, Esther Natalie Oliva, PhD, Roger Else, Jonathan Kell, MD, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Daniel Jennings, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Stewart McConnell, Catherine Langton, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2019) 134 (Supplement_1): 3484.

https://doi.org/10.1182/blood-2019-129030

Published: 2019

Journal Articles

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Yi Ying Regina Li, MD, Soo Jin Seung, Stephanie Y Cheng, Matthew Cheung, MDMSc, Nicole Mittman, PhD MSc

Blood (2019) 134 (Supplement_1): 4745.

https://doi.org/10.1182/blood-2019-131407

Published: 2019

Journal Articles

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2019) 134 (Supplement_1): 330.

https://doi.org/10.1182/blood-2019-127568

Published: 2019

Journal Articles

HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice

Pushpendra Goswami, PhD MSc, BPharm, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Tatyana Ionova, PhD, Esther Natalie Oliva, MD, Adele K Fielding, MBBS,PhDFRCP,FRCPath, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham Collins, MD PhD, Stewart McConnell, Catherine Langton, Daniel Jennings, Roger Else, William J. Kell, MD

Blood (2017) 130 (Supplement 1): 2176.

https://doi.org/10.1182/blood.V130.Suppl_1.2176.2176

Published: 2017

Journal Articles

Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation

Pushpendra Goswami, B.Pharmacy, MSc, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Jonathan Kell, MD, Saad Al-Ismail, MD, Esther Oliva, MD, Tatyana Ionova, PhD, Roger Else, Marina Karakantza, MD, Daniel Jennings, Anita Waldmann

Blood (2016) 128 (22): 5985.

https://doi.org/10.1182/blood.V128.22.5985.5985

Published: 2016

Journal Articles

National Epidemiology of Inpatient Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012

Kathan Dilipbhai Mehta, MBBS, MPH, Sameer A. Parikh, MD, Hong Wang, PhD, Rahul Atul Parikh, MD PhD, Roy E. Smith, MD

Blood (2015) 126 (23): 630.

https://doi.org/10.1182/blood.V126.23.630.630

Published: 2015

Journal Articles

Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey

Blood (2015) 126 (23): 4887.

https://doi.org/10.1182/blood.V126.23.4887.4887

Published: 2015

Journal Articles

Immune checkpoint blockade in hematologic malignancies

Philippe Armand

Blood (2015) 125 (22): 3393–3400.

https://doi.org/10.1182/blood-2015-02-567453

Published: 2015

Journal Articles

High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders

Antonella Caivano, Luciana De Luca, Ilaria Laurenzana, Francesco La Rocca, Vittorio Simeon, Stefania Trino, Annalisa Morano, Fiorella D'Auria, Pellegrino Musto, MD, Luigi Del Vecchio

Blood (2014) 124 (21): 2917.

https://doi.org/10.1182/blood.V124.21.2917.2917

Published: 2014

Journal Articles

Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy

Rangaswamy Chintapatla, MD, Leticia Varella, M.D, Peter Wiernik, MD, Valerie Rusciano, R.N, Janice P. Dutcher, MD

Blood (2012) 120 (21): 5086.

https://doi.org/10.1182/blood.V120.21.5086.5086

Published: 2012

Journal Articles

Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM)

Farhad Ravandi, MD, Arnaud Pigneux, MD, PhD, Daniel J. DeAngelo, MD, PhD, Hervé Dombret, MD, Jacques Delaunay, MD, Xavier Thomas, MD, PhD, Tapan Kadia, Christian Luepfert, PhD, Ekaterine Asatiani, MD, Margarita Donica, MSc, Hagop M. Kantarjian, B. Douglas Smith, MD

Blood (2011) 118 (21): 1554.

https://doi.org/10.1182/blood.V118.21.1554.1554

Published: 2011

Journal Articles

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

Milena Sant, Claudia Allemani, Carmen Tereanu, Roberta De Angelis, Riccardo Capocaccia, Otto Visser, Rafael Marcos-Gragera, Marc Maynadié, Arianna Simonetti, Jean-Michel Lutz, Franco Berrino, and the HAEMACARE Working Group

Blood (2010) 116 (19): 3724–3734.

https://doi.org/10.1182/blood-2010-05-282632

Published: 2010

Includes: Supplemental data

Journal Articles

Survival of Myeloid Malignancies in EUROPE: Results of the HAEMACARE Project.

Marc Maynadié, MD, PhD, Roberta De Angelis, Claudia Allemani, Riccardo Capocaccia, Jean Michel Lutz, Rafael Marcos Gragera, Carmen Tereanu, Otto Visser, MD, Milena Sant

Blood (2009) 114 (22): 3911.

https://doi.org/10.1182/blood.V114.22.3911.3911

Published: 2009

Journal Articles

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Linda R Taggart, MD, Pierre K Isogai, B.Sc, Nancy Risebrough, B.A., Nicole Mittmann, MSc, PhD, Anita R Rachlis, MD, Kevin R Imrie, MD, Matthew C Cheung, MD

Blood (2009) 114 (22): 1916.

https://doi.org/10.1182/blood.V114.22.1916.1916

Published: 2009

Journal Articles

Primary Extranodal Lymphoma: Revised Incidence, Location, Histological Classification and Survival in Zaragoza (Spain), 1992–2002

Pilar Giraldo, MD, PhD, Esther Franco-Garcia, Ramiro Alvarez, Gloria Garcia-Carpintero, Mercedes Pascual, Carmen Martos

Blood (2008) 112 (11): 4674.

https://doi.org/10.1182/blood.V112.11.4674.4674

Published: 2008

Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3318.

https://doi.org/10.1182/blood.V108.11.3318.3318

Published: 2006

NARROW

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Resource Utilization and Costs in the Care of Patients with Hematologic Malignancies

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice

Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation

National Epidemiology of Inpatient Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012

Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey

Immune checkpoint blockade in hematologic malignancies

High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders

Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy

Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM)

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

Survival of Myeloid Malignancies in EUROPE: Results of the HAEMACARE Project.

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Primary Extranodal Lymphoma: Revised Incidence, Location, Histological Classification and Survival in Zaragoza (Spain), 1992–2002

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only